Enzytec launches solution that eliminates the use of Level 2 biosecurity chambers in rapid tests for COVID

For the development and evaluation of tests for COVID-19, one of the major barriers that manufacturers of IVD kits encounter, due to current legislation, is the need to use Biosafety Level 2 chambers and procedures in their Quality Control and R&D laboratory. A used alternative, also bureaucratic and with high cost, is sending the products for testing in external clinical laboratories.

Enzytec, after realizing this need from its customers, carried out numerous tests with its R&D team and has just launched the SARS-COV-2 Recombinant N Antigen on the market. Consisting of the N protein of the capsid of the SARS-COV-2 virus, of bacterial recombinant origin, the antigen presents low risks of manipulation because it does not present viral infective potential, eliminating the use of NB-2 procedures and speeding up the research, development and evaluation of products designed for SARS-COV-2 antigen testing. .. This protein can also be used in the manufacture of standards and controls for the antigen in ELISA kits, CLIA or other IVD and Life Sciences products.

Currently, this solution is already being used by some ENZYTEC customers. With excellent stability and test reproducibility, the antigen makes it possible to verify variations between batches and between tests of the same batch, safely and quickly.

So if you were looking for a cost effective, safe and fast solution to evaluate your tests for COVID-19 antigen, this is the opportunity your company was missing! Contact us to find out more!

Photo: Evaluation of rapid test for COVID-19 using SARS-COV-2 Recombinant N Antigen ENZYTEC

Any questions? Contact us
and you will be ansewered soon!